期刊
CURRENT OPINION IN GASTROENTEROLOGY
卷 30, 期 4, 页码 385-390出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOG.0000000000000077
关键词
emerging therapy; inflammatory bowel disease; novel treatments
资金
- Abbott Corporation/Abbvie
- Alaven
- Bristol-Myers Squibb
- Elan
- Ferring
- Hospira
- Jansen Orthobiotech
- Luitpold/American Regent
- Millennium Pharmaceuticals
- Ono Pharmaceuticals
- Pfizer Pharmaceuticals
- Prometheus Laboratories, Inc.
- Salix Pharmaceuticals
- Santarus
- Shire Pharmaceuticals
- Takeda
- UCB
- Warner Chilcotte
Purpose of review The increased understanding of the molecular mechanisms that are responsible for inflammatory bowel disease (IBD) has led to a wide range of potential therapeutic targets for this condition. Physicians treating individuals with Crohn's disease and ulcerative colitis have a growing armamentarium of options to choose from in managing these patients. This article aims to summarize the relevant literature in the area of emerging therapy in IBD. Recent findings The widespread use of antitumor necrosis factor medications brought a landmark change in the treatment of IBD. More recently, several drugs have been shown to provide benefit in IBD in phase III studies by blocking other antiinflammatory pathways. The most likely new medications that will be available include vedolizumab for ulcerative colitis and ustekinumab for Crohn's disease, which target cellular adhesion and inflammatory cell signaling, respectively. Other promising drugs focus on blockade of Janus kinase, inhibition of various chemokines, and biologic therapy such as hematopoietic stem cell transplants and mesenchymal cell infusions. Summary The growing understanding of the pathogenesis of IBD has led to new molecular targets for therapy. Over the next decade, the number of treatments available will grow, targeting cellular adhesion, protein regulation, inflammatory signal pathways, and immune tolerance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据